Clinical Trial Update: Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression. [Phase 2]

View source ↗

Summary

A Phase 2 trial in recurrent ovarian cancer evaluating two doses of a study drug with low-dose cyclophosphamide after response to platinum-based second-line the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Snippet

Sponsor: EMD Serono | Conditions: Ovarian Cancer | Phase 2 | Status: WITHDRAWN